Compare Gartner Inc (IT) vs Moderna, Inc. (MRNA) Price & Performance

Gartner (IT) trades at $185.09, down 4.18% today, following a strong earnings beat in Q2 2026 with EPS of $4.37 versus $3.76 expected. The stock shows a bullish technical trend but trades above the consensus price target of $172.80. Recent news highlights a shareholder investigation and raised full-year EPS guidance, creating mixed sentiment amid strong profitability metrics like a 69.63% gross margin and 113.58% ROE.

The outlook is cautiously optimistic given earnings momentum and valuation discounts, but risks include consulting segment weakness, negative net cash flow trends, and the fiduciary investigation. Upside depends on sustained execution against guidance, while downside could stem from growth deceleration or legal overhangs.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.